Sarepta Therapeutics Inc. (SRPT)

93.62
NASDAQ : Health Technology
Prev Close 95.98
Day Low/High 92.00 / 97.47
52 Wk Low/High 72.05 / 158.80
Avg Volume 912.70K
Exchange NASDAQ
Shares Outstanding 77.78M
Market Cap 7.23B
EPS -9.70
Div & Yield N.A. (N.A)
My Game Plan Is to Not Trust That Upside

My Game Plan Is to Not Trust That Upside

There has been enough technical damage done lately.

Shark Bites: You Don't Want to Play the Gambler Today

Shark Bites: You Don't Want to Play the Gambler Today

This is one of those days when it may pay to walk away.

Market Is Home on the Range Again

Market Is Home on the Range Again

Emotion of yesterday's collapse is pretty much gone.

Shark Bites: Market Needs a Bounce in Its Step

Shark Bites: Market Needs a Bounce in Its Step

Biotechnology continues to be a bright spot.

Watching Financials and Biotech in This Tepid Market

Watching Financials and Biotech in This Tepid Market

Keep an eye on the pattern of morning weakness and afternoon strength.

Market Action Is Boring but Necessary

Market Action Is Boring but Necessary

After yesterday's surprise pullback, this is the sort of consolidation we need.

Market Taking a Break, but Probably Not for Long

Market Taking a Break, but Probably Not for Long

Today is more about stock picking.

Sarepta upgraded at Leerink

More Selling Pressure, But No Rush for the Exits

More Selling Pressure, But No Rush for the Exits

If you play strong defense, be prepared to change course very quickly.

The Contrary Indicators Are Piling Up

The Contrary Indicators Are Piling Up

But it is all about timing, and so far there is no indication that this extended market is about to turn.

Some Stock Picks on This Morning's Dip

Some Stock Picks on This Morning's Dip

It will be interesting to see today if afternoon strength occurs once again.

Is Sarepta Actually Competing with Marathon?

Is Sarepta Actually Competing with Marathon?

TheStreet's Adam Feuerstein defends Sarepta Therapeutics

The Fed's Dilemma Is Quite Obvious

The Fed's Dilemma Is Quite Obvious

The Fed cannot move interest rates until fiscal policy is clear.

Trading Action Has Improved, Here's What I Am Playing

Trading Action Has Improved, Here's What I Am Playing

Market players are sorting out the winners and losers, and that produces good opportunities if we keep on digging.

Here's a New List of Stocks That Show Bullish or Bearish Reversal Patterns

Here's a New List of Stocks That Show Bullish or Bearish Reversal Patterns

These companies show signs of a change of direction.

Surge From Bank Earnings Doesn't Last

Surge From Bank Earnings Doesn't Last

Earnings and inauguration may be catalysts for the market.

Stocks Build on Early Gains in Midday Trading, Nasdaq Moves Further into Record Territory

Stocks Build on Early Gains in Midday Trading, Nasdaq Moves Further into Record Territory

Stocks were climbing at midday on Tuesday, and the Nasdaq moved further into record territory.

Sarepta Provides Details About its Duchenne Drug Launch and Eases Some Fears

Sarepta Provides Details About its Duchenne Drug Launch and Eases Some Fears

Sarepta Therapeutics provides early sales numbers for its drug to treat DMD, and they topped expectations.

Rev's Forum: The Fed Isn't Convinced the Trump Rally Is Justified

Rev's Forum: The Fed Isn't Convinced the Trump Rally Is Justified

Its members are skeptical about the market celebration and are not going to commit to a course of rate hikes until they have more data.

Trying to Knock Out Some Individual Trades, but it Is not Easy

Trying to Knock Out Some Individual Trades, but it Is not Easy

If the indices take out yesterday's lows I'll be very bearish very quickly.

Market Sees Rise in Performance Anxiety

Market Sees Rise in Performance Anxiety

I've got my eye on steel and biotechnology names to put cash to work.

Shark Bites: We Knew Today Would Be Slow, but Come On…

Shark Bites: We Knew Today Would Be Slow, but Come On…

Don't force it; there's no energy.

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 tweets by TheStreet's Adam Feuerstein kept us informed and entertained. From an unexpected twist on New Year's day with MannKind to J.P. Morgan's Healthcare conference to Bristol-Myers Squibb's oops!

Trader Be Nimble, Trader Be Quick

Trader Be Nimble, Trader Be Quick

The trading action remains quite tedious, though there are short-term opportunities out there.

Shark Bites: Market Isn't Giving Us Much

Shark Bites: Market Isn't Giving Us Much

You have to dig below the surface and develop a feel for what stocks are leading.

Ignore Market Jitters, Let Price Action Be the Guide

Ignore Market Jitters, Let Price Action Be the Guide

Equities are holding up well, despite concerns that good economic news increases the chances of a rate hike.

Trending Tickers: SDRL, P, SMMT, SRPT

Trending Tickers: SDRL, P, SMMT, SRPT

SeaDrill's chairman and top shareholder seems willing to lend a hand to keep the company's leverage in check.

Summit Therapeutics Soars on Sarepta Deal

Summit Therapeutics Soars on Sarepta Deal

Summit Therapetuics shares skyrocketed Tuesday on word that it has entered into an exclusive licensing agreement with drugmaker Sarepta Therapeutics.

Shark Bites: Market Responds With 'Deutsche Who?'

Shark Bites: Market Responds With 'Deutsche Who?'

Report of settlement turns the market.

Selling Into Strength Can Be a Great Strategic Move

Selling Into Strength Can Be a Great Strategic Move

We are seeing lower lows in the indices as I write.